OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group